Aldeyra Therapeutics Inc

$3.25 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in developing immune-modulating therapies to treat ocular and systemic diseases. The Company's lead product candidate, reproxalap, is a treatment in late-stage development for dry eye disease (DED) and allergic conjunctivitis (AC). It has additional product candidates in development for proliferative vitreoretinopathy (PVR), primary vitreoretinal lymphoma (PVRL) and other retinal diseases, autoimmune disease, and cancer. The Company's product development pipeline is focused on immune-mediated ocular diseases and select systemic diseases and encompasses three biological mechanisms of action: reactive aldehyde species (RASP) inhibition, dihydrofolate reductase (DHFR) inhibition, and protein chaperome (CHP) inhibition. The immunological activity of its product candidates generally leads to diminished levels of pathological inflammation via down-regulation of immune cell activation or proliferation.

Stock Analysis

last close $3.25
1-mo return -7.1%
3-mo return -60.1%
avg daily vol. 1.06M
52-week high 15.95
52-week low 3.24
market cap. $220M
forward pe -
annual div. -
roe -36.9%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 70.6%
baraka

Subscribe now for daily local and international financial news

Subscribe